Sanofi, Regeneron score fast FDA review for Dupixent in eosinophilic esophagitisnews2022-04-04T15:08:02+00:00April 4th, 2022|Fierce Pharma|
Alnylam’s Onpattro follow-on delayed thanks to manufacturing holdup at FDAnews2022-04-04T14:25:06+00:00April 4th, 2022|Fierce Pharma|
Sanofi launches DE&I board with outside advisors, the first of its kind in pharmanews2022-04-04T13:23:16+00:00April 4th, 2022|Fierce Pharma|
Merck, nearing completion of $1B Gardasil manufacturing push, eyes 2023 to double production—againnews2022-04-04T12:41:53+00:00April 4th, 2022|Fierce Pharma|
In major shake-up, Novartis combines pharma and oncology units, leaving 3 top execs without jobsnews2022-04-04T08:30:00+00:00April 4th, 2022|Fierce Pharma|
Imfinzi maker AstraZeneca adds caregivers to refreshed ‘Notes’ campaign for lung cancer patientsnews2022-04-03T19:06:54+00:00April 3rd, 2022|Fierce Pharma|
ACC: Lexicon hopes sotaglifozin cardio data will set its drug apart from SGLT2 rivalsnews2022-04-02T19:00:55+00:00April 2nd, 2022|Fierce Pharma|
ACC: Lexicon hopes sotagliflozin cardio data will set its drug apart from SGLT2 rivalsnews2022-04-02T19:00:55+00:00April 2nd, 2022|Fierce Pharma|
Key Success Metrics for Clinical Development Organizationsnews2022-04-01T20:01:28+00:00April 1st, 2022|Fierce Pharma|
Amid Exkivity launch, Takeda beefs up in-house digital content team, AI to educate oncologistsnews2022-04-01T18:13:21+00:00April 1st, 2022|Fierce Pharma|
